NASDAQ:MBRX

Moleculin Biotech Q2 2025 Earnings Results & Report

Moleculin Biotech logo
$6.83 -0.31 (-4.34%)
Closing price 03:59 PM Eastern
Extended Trading
$6.96 +0.14 (+1.98%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moleculin Biotech missed analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$245.00 versus the -$195.00 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
8:00 AM ET

Moleculin Biotech EPS Results

Actual EPS
-$245.00
Consensus EPS
-$195.00
Beat/Miss
Missed by -$50.00
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Moleculin Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Moleculin Biotech Q2 2025 Earnings FAQ

Moleculin Biotech (NASDAQ:MBRX) reported earnings of -$245.00 per share for Q2 2025, missing the consensus estimate of -$195.00. The report was announced on Tuesday, August 12, 2025.

Moleculin Biotech Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Moleculin Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email.

About Moleculin Biotech

Moleculin Biotech (NASDAQ:MBRX) is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies.

The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity.

Another candidate, WP1066, is an investigational immunotherapy designed to inhibit STAT3, a protein involved in tumor growth and immune response. It is being explored for brain tumors, including glioblastoma. Moleculin is led by co-founder and Chief Executive Officer Walter Klemp. Its drug candidates remain investigational and are not approved for commercial use.

View Moleculin Biotech Profile